title: Relevance of tumor-infiltrating lymphocytes in breast cancer.
abstract: While breast cancer has not been considered a cancer amenable to immunotherapeutic approaches, recent studies have demonstrated evidence of significant immune cell infiltration via tumor-infiltrating lymphocytes in a subset of patient tumors. In this review we present the current evidence highlighting the clinical relevance and utility of tumor-infiltrating lymphocytes in breast cancer. Retrospective and prospective studies have shown that the presence of tumor-infiltrating lymphocytes is a prognostic marker for higher responses to neoadjuvant chemotherapy and better survival, particularly in triple negative and HER2-positive early breast cancer. Further work is required to determine the immune subsets important in this response and to discover ways of encouraging immune infiltrate in tumor-infiltrating lymphocytes-negative patients.
authors: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
authors: Sathana
authors: S
authors: Dushyanthen
authors: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
authors: Paul A
authors: PA
authors: Beavis
authors: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
authors: Peter
authors: P
authors: Savas
authors: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
authors: Zhi Ling
authors: ZL
authors: Teo
authors: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
authors: Chenhao
authors: C
authors: Zhou
authors: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
authors: Mariam
authors: M
authors: Mansour
authors: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.|Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
authors: Phillip K
authors: PK
authors: Darcy
authors: Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. sherene.loi@petermac.org.|Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia. sherene.loi@petermac.org.|Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. sherene.loi@petermac.org.
authors: Sherene
authors: S
authors: Loi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism*; D020360:Neoadjuvant Therapy; D011446:Prospective Studies; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor